Background: High birthweight is an established risk factor for childhood leukaemia. Its association with other childhood cancers is less clear, with studies hampered by low case numbers. Methods: We used two large independent datasets to explore risk associations between birthweight and all subtypes of childhood cancer. Data for 16 554 cases and 53 716 controls were obtained by linkage of birth to cancer registration records across five US states, and 23 772 cases and 33 206 controls were obtained from the UK National Registry of Childhood Tumours. US, but not UK, data were adjusted for gestational age, birth order, plurality, and maternal age and race/ethnicity. Results: Risk associations were found between birthweight and several childhood cancers, with strikingly similar results between datasets. Total cancer risk increased linearly with each 0.5 kg increase in birthweight in both the US [odds ratio 1.06 (95% confidence interval 1.04, 1.08)] and UK
Introduction
The causes of childhood cancer are largely unknown. The early age at onset of many childhood cancers, 1 and presence of premalignant leukaemia clones at birth, 2 suggest that prenatal influences play a role in their aetiologies. High birthweight is associated with risk of acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML) in childhood. 3, 4 It has been proposed that higher levels of circulating growth factors in pregnancies leading to big babies may have oncogenic effects on the developing immune system, increasing the risk of progression to leukaemia. 5, 6 Risk of central nervous system (CNS) tumours, 7 neuroblastoma 8 and Wilms tumour 9 may also be linked to birthweight, suggesting an underlying and potentially key relationship between in utero tissue growth/development and cancer risk. However, low case numbers have been a limitation of these studies, and controversy remains. Little is known about the risk relationship between birthweight and other childhood tumours.
Here we have used two large, independent populationbased datasets to analyse the relationship between birthweight and the entire spectrum of childhood tumours.
Methods

US data collection
Data were pooled from case-control studies conducted in California, Minnesota, New York, Texas and Washington. 10 Cases were identified from population-based cancer registries, and controls were randomly selected from birth records, with ratios ranging from 1:1 to 10:1. Frequency matching was used for all states apart from California, where individual matching was employed. All states matched by year of birth; California and Texas also matched by sex. Cases diagnosed and controls dying neonatally were excluded, as were most with Down syndrome (DS) recorded on their birth certificates (not recorded in Texas or Washington before 1984 and 1989, respectively). The remaining 17 672 cases and 57 966 frequency-matched controls are summarized in Table 1 . Birthweight, gestational age, plurality, gender, birth order, year of birth, and maternal age and race were obtained from birth records. Only subjects with values for each of these were included in the analysis. Gestational ages calculated from last menstrual period (LMP) and clinical date estimates were provided by four states (California only the LMP). Gestational age calculation prioritized the LMP estimate when available. 10 All subjects with plausible birthweights and gestational ages 11, 12 were included in the analysis, but birthweights recorded as <0.5 or !6.0 kg and gestational ages recorded as <20 or >45 weeks were considered inaccurate and treated as missing. Also excluded were birthweights for gestational age suggested to be unreliable by expert guidelines. 10 16 554 cases and 53 716 controls remained after exclusions.
UK data collection
The UK National Registry of Childhood Tumours (NRCT) includes all malignancies and brain tumours diagnosed in children aged 0-14 years while domiciled in England, Wales and Scotland from 1962 (and in Northern Ireland from 1993) to 2010. 13 Birth registration information for most NRCT cases was routinely obtained from the Office for National Statistics and the General Registry Office Scotland. One (or two since 2000) control birth records were also routinely selected, individually matched on sex, district and subdistrict of registration and being born within 6 months of the case. No controls were diagnosed with childhood cancer at time of selection. Birthweight was available for 95% of England and Wales NRCT cases and controls born and diagnosed 1980-2007 (25 649 cases, 34 082 controls, Table 1 ). Birth registration records available to the NRCT do not routinely document DS, so these children were not excluded from the study. As for US data, birthweights recorded as <0.5 kg and !6.0 kg were excluded. The informative sets included 23 772 cases and 33 206 controls.
Statistical analysis
The International Classification of Childhood Cancers third edition was used to classify tumour subtypes (Tables 2-6, Figure 1, and Supplementary Tables S1-S3 available at IJE online). US data were analysed using unconditional logistic regression in SAS 9.2 with odds ratios (ORs) adjusted for gender, state and year of delivery. Further adjustment was made for gestational age. Maternal age, plurality, birth order and maternal race/ethnicity were also included in the analysis since they are established/suspected risk factors for several childhood cancers, [14] [15] [16] [17] with known association to birthweight. 18 ORs and 95% confidence intervals (CIs)
were calculated considering birthweight as a continuous variable (trend per 0.5 kg increase in birthweight) as well as a categorical variable (with 3.00-3.49 kg as the reference). UK data were analysed using STATA 11, using conditional logistic regression based on the individually matched case-control sets. Birth registration records from England and Wales do not routinely document gestation, maternal age, plurality, birth order or maternal race/ethnicity, so we were unable to adjust for these potential confounders for this dataset. ORs and 95% CIs were calculated considering birthweight as a continuous and a categorical variable, as for the US data.
Fractional polynomial approaches examined all cancer subtypes with at least 100 cases, using R for US data and STATA 11 for UK data. These methods allowed us to test transformations using powers in the set (À2, À1, À0.5, 0, 0.5, 1, 2, 3) to determine the best-fitting model, including up to two terms in each. Tests of difference in deviance determine whether the fit is significantly worse than a oneterm model. If complex models performed no better, the linear term was maintained. All US models included terms for state, birth year and sex as matching variables. Modelling UK data necessarily included the control matching variables. 
Results
As expected, across the entire study population most cancer types were more prevalent in males, particularly the lymphomas and hepatic tumours ( Table 2) . Renal tumours and carcinomas/melanomas occurred more frequently among females, whereas retinoblastomas were distributed equally between the sexes. These distribution patterns were similar between US and UK datasets for all but the germ cell tumours, which displayed a contrasting male and female dominance in the USA and the UK, respectively. Mean age at diagnosis was comparable between datasets for each cancer, as was the proportion of individuals in each birthweight category. Mean birthweights were slightly greater for US compared with UK babies (3.41 kg vs 3.34 kg for controls, 3.42 kg vs 3.38 kg for total cancer cases). This pattern persisted for most cancer types, although the reverse was seen for carcinomas/melanomas and hepatic tumours, and there was negligible difference between datasets for the lymphomas, bone tumours and retinoblastomas. US and UK datasets were analysed independently to determine risk associations between birthweight and risk of childhood cancer. Analysis of US data included adjustment for gestational age, maternal age, plurality, birth order and maternal race/ethnicity. This was not possible for the UK analysis, since information on these variables was not available.
Childhood cancers that associate with birthweight in both datasets
In both datasets, increasing birthweight associated with an increased risk of total childhood cancer, with each 0.5 kg increase in birthweight elevating risk by 6% (Table 3) . Risk associations were observed for several tumour subgroups. For most there was a striking correlation between datasets, even though only US data were adjusted for potential confounders (Table 3) .
Increasing birthweight associated with risk of leukaemias, CNS tumours, renal tumours and soft tissue sarcomas, but risk appeared specific to subsets of each. Leukaemia risk was strongest for the lymphoid leukaemias (USA: OR 1.11, UK: 1.08 per 0.5 kg increase in birthweight) and for children diagnosed age 1-14 years (USA: 1.10, UK: 1.08 per 0.5 kg increase). For CNS tumours, risk was most notable for astrocytomas (USA: 1.06, UK: 1.09 per 0.5 kg increase), although risk of intracranial and intraspinal embryonal tumours was also strong in the UK (1.09 per 0.5 kg increase). To understand the weaker association between this tumour type and birthweight in the USA, we investigated whether the calculated risk was influenced by confounder adjustment. Without adjustment for gestational age, maternal age, plurality, birth order and maternal race/ethnicity in the US analysis, the risk association strengthened (1.07 per 0.5 kg increase, Table 3 ), suggesting an influence of one or more of these variables in this International Odds ratios (95% confidence intervals), considering birthweight as a continuous variable. Odds ratios whose 95% confidence intervals are below the null value (1) are bold italic.
shown in Table 3 (Supplementary Table S1 , available as Supplementary data at IJE online). For neuroblastoma, risk in both datasets was increased when considering birthweight as a continuous variable, but was particularly strong for high birthweight babies, especially in the USA (Table 4) . Analysis of US data without adjustment for potential confounders made little difference to calculated risks (Table 4) . Neuroblastoma primarily affects young children, with approximately 85% diagnosed at 4 years of age. 1 This age group is disproportionately represented in the US dataset because of the Californian contribution (Table 1) . Omitting California data from the analysis weakened risk associations with high birthweight ( Table 4 ), suggesting that risk of neuroblastoma is particularly increased in younger children.
Childhood cancers that associate with birthweight in either dataset
Slight discrepancies between datasets were observed for some tumour types (Table 5 ). For lymphomas, strong risk associations were observed with increasing birthweight in the UK, particularly for Burkitt lymphoma (1.28 per 0.5 kg increase), whereas risk associations for the USA remained weak regardless of adjustment for potential confounders and omission of the California dataset. Each 0.5 kg increase in birthweight was also associated with increased risk of total germ cell tumours, but the strength of the association for different tumour subtypes varied between datasets. Intracranial and intraspinal germ cell tumours were most strongly associated with increasing birthweight in the UK (1.19 per 0.5 kg increase). Risk associations for this tumour type in the USA were weaker, regardless of confounder adjustment or exclusion of the California dataset. Malignant extracranial and extragonadal germ cell tumour risk, on the other hand, was most evident in the USA (1.38 per 0.5 kg increase), and remained so without confounder adjustment (1.36 per 0.5 kg increase) or minus the California dataset (1.37 per 0.5 kg increase). For other malignant epithelial neoplasms and malignant melanomas, a strong association with increasing birthweight was observed in the UK, driven by malignant melanomas (1.35 per 0.5 kg increase). This was not observed in the USA, irrespective of confounder adjustment or exclusion of California's data. Increased risk of other and unspecified malignant neoplasms was strongest for the USA, but numbers in both datasets were small and the tumours included are heterogeneous. These dataset-specific Figure 1 . Childhood tumours that demonstrate non-linear risk relationships with birthweight. Fractional polynomial models were used to explore whether tumours displayed non-linear risk relationships with birthweight. Shown are tumours for which these fit better than the linear model. The plots illustrate the shape of the relationship described by the best-fit polynomial models for (A) US data: hepatoblastoma (log x and x3 terms) and Wilms tumour (x3 and x3 log x terms); and (B) UK data: hepatoblastoma (x2 term), intracranial and intraspinal germ cell tumours (x3 term) and acute myeloid leukemia (x2 and x3 terms).
results were also generally observed when considering risk by birthweight category (Supplementary Table S2 , available as Supplementary data at IJE online).
Childhood cancers that appear to be independent of birthweight
In contrast to the above childhood cancers, we did not observe strong associations between increasing birthweight and risk of retinoblastomas or malignant bone tumours, in either dataset (Table 6 ). Risks remained weak for both of these tumour types when birthweight was considered categorically (Supplementary Table S3 , available as Supplementary data at IJE online).
Complex risk associations between some childhood cancers and birthweight
Finally, we tested whether fractional polynomial regression models fitted the data better than simple linear ones. Although a linear risk relationship best described associations for the majority of tumours, non-linear models were a better fit for some disease subtypes (Figure 1) . In both datasets, low birthweight was particularly associated with hepatoblastoma risk. In contrast, a marked risk association with high birthweight was noted for Wilms tumour in the USA and intracranial and intraspinal germ cell tumours in the UK. Although AML was not associated with birthweight categorically or linearly in either dataset, a U-shaped association was observed within the UK.
Discussion
Here we have shown that birthweight is a risk factor for childhood leukaemia, CNS tumours, renal tumours, soft tissue sarcomas and hepatic tumours, and may also associate with risk of neuroblastoma, lymphoma, germ cell tumours and other malignant neoplasms/melanomas. Risk appears to be specific to subtypes of each of these tumours. In total, the associated subtypes constitute roughly half of all childhood cancers.
Results in relation to other studies
Childhood leukaemia Risk relationships between childhood leukaemia and birthweight are well characterized. 3, 4, 19 Our results confirm that high birthweight increases risk of ALL, but suggest that the relationship with AML may not be straightforward. The U-shaped risk association observed within the UK, which was also noted in a metaanalysis, 3 was not evident in the USA. Stratification of US data by age at diagnosis did reveal a strong U-shaped association for children diagnosed when aged 5-14 years [OR 3.27 (95% CI 1.34, 7.96) for <2.0 kg; 1.63 (1.13, 2.36) for !4.0 kg; compared with the 3.00-3.49 kg reference group], but not for those aged 4 years. This is based on low case numbers, but indicates that variations in age distribution between datasets may influence the observed risks. Another consideration is confounding by DS, which is independently associated with low birthweight 20 and risk of myeloid leukaemia. 21 In our study, cases with DS were excluded from the US data, but not from the UK data due to incomplete recording of DS on UK birth records. Association with low birthweight decreased when known DS cases were omitted from the UK, and increased when DS cases were included in the USA-with negligible effect on associations with high birthweight (data not shown). This may indicate that the increased risk of AML observed for low birthweight babies may be attributable to DS. Our results also indicate that birthweight is not a strong risk factor for infant leukaemias. We previously reported that birthweight specifically increases risk of leukaemias with high hyperdiploidy and t(1;19) translocations, 4 and others have also observed differences in risk according to cytogenetic feature. 19 These chromosomal abnormalities are underrepresented in infant leukaemias, 22 which may explain why birthweight does not significantly influence risk for this age group.
Childhood CNS tumours, renal tumours and neuroblastoma Although results of previous individual studies of birthweight and risk of CNS tumours, renal tumours and neuroblastoma have varied significantly, meta-analyses of these tumour types 7-9 generally align with our results. However, the comparison of two independent datasets in our study has highlighted potential factors that may help explain previous inconsistencies. For CNS tumours, although we and others 7 find that high birthweight associates with risk of astrocytomas but not ependymomas, the evidence for CNS embryonal tumours is more varied. Even within our own study, we observed variation in risk between US and UK datasets. Given that these embryonal tumours are exceptionally heterogeneous, 23 this inconsistency may be due to varying proportions of tumour subgroups within datasets. However, as discussed below, our results also indicate that risk of this subtype is influenced by adjustment for gestational age, which may also explain the variation observed in the literature. A meta-analysis of Wilms tumour concluded an increased risk in high birthweight babies. 9 In our study, risk was greatest among the very high birthweight in the USA, where 5% of cases weighed >4.5 kg at birth. In the UK, risk increased less dramatically (i.e. linearly) with birthweight, with only 3% of cases weighing >4.5 kg. Thus the proportion of cases with very high birthweights may influence the shape of the risk relationship. Wilms tumour is associated with a number of overgrowth syndromes that are characterized by very high birthweight. 24 Although we did not have the clinical data to explore this, it is possible that cases with these syndromes are more prevalent among our US population, driving the strong association with very high birthweight. For neuroblastoma, meta-analyses have suggested a risk association with low birthweight, 8 although our study did not find evidence of this. Of note, we observed stronger risk associations between high birthweight and neuroblastoma when the majority of cases were <5 years old.
Results may therefore differ because of differences in the age distribution across studies.
Childhood lymphoma
Literature on risk associations between birthweight and childhood lymphoma has been particularly contradictory.
A recent meta-analysis concluded no significant risk associations with birthweight, 25 but studies have differed markedly with respect to disease stratification and adjustment for confounders. 19, 25 Furthermore, lymphoma classification has seen significant uncoordinated changes over the past 60 years, 26, 27 which has undoubtedly impacted on the results of these studies. Here we have considered the largest number of lymphomas to date, with over five times as many cases as the previous largest single study. 28 We observe that risk of lymphoma strongly associates with high birthweight within the UK, particularly for Burkitt lymphoma. Why this association is weaker in the USA is unclear. There is a slightly younger age distribution among US cases (35% aged 1-4 years, 37% 5-9 and 27% 10-14) compared with the UK (27% 1-4, 42% 5-9 and 31% 10-14), which might suggest that earlier onset lymphomas are driven by factors other than birthweight. It may also be that, like the leukaemias, 4, 19 Although we did not have information on the EBV status of the cancers included in our analysis, measures of EBV seroprevalence among the childhood population during our study period report a higher rate in the USA (64% of 12-14-year-olds) 31 compared with the UK (54% of 10-14-year-olds). 32 One could therefore speculate that our data indicate that risk association with birthweight is more significant for non-EBV-associated lymphomas. Thus although we conclude that birthweight is a risk factor for childhood lymphoma, further studies considering age at diagnosis, diagnostic subgroup and EBV status are warranted.
Rare childhood cancers
For the less common childhood cancers, low case numbers have hampered previous investigations. Results of limited studies exploring soft tissue sarcomas 28, [33] [34] [35] and germ cell tumours [36] [37] [38] [39] [40] are inconsistent, and to date there has been no investigation into risk associations between birthweight and other malignant neoplasms/melanomas in children.
Our data indicate that birthweight is a risk factor for subsets of these diseases, but that some of these relationships may be complex and possibly influenced by other factors. We found that increasing birthweight associates with risk of soft tissue sarcomas, specifically the embryonal rhabdomyosarcomas. Risk relationships with malignant melanomas and germ cell tumours appear to be more complex, with contrasting results between our datasets that are not explained by variation in gestational age, maternal age, plurality, birth order or maternal race/ethnicity. Classification issues may explain some of these discrepancies, particularly for malignant melanomas. These tumours can be difficult to distinguish from benign growths in children, 1 so it is possible that some misclassified benign melanomas were included in our analysis, thus skewing results. There may also be genetic or geographical factors that make the UK population more susceptible to increased risk of disease in high birthweight babies. Of note, high birthweight was recently shown to associate with risk of malignant melanoma in adults in a UK-based study. 41 The pronounced non-linear association between intracranial and intraspinal germ cell tumours and high birthweight, observed only in the UK, is likely to be driven by the high proportion of cases with very high birthweights (3.0% >4.5 kg) compared with controls (0.3%), which was not observed in the USA (3.5% cases >4.5 kg, compared with 2.2% controls). The reason for this difference is unclear. We did note a higher proportion of female cases of this tumour type in the UK (41.1%) compared with the USA (33%), and since birthweight has been shown to affect risk in a sex-dependent manner for the haematological malignancies, 19 the higher risk association seen in the UK may indicate that risk is more prominent in females. Dataset differences in sex distribution were not observed for malignant extracranial and extragonadal germ cell tumours (data not shown), which only displayed a risk association with birthweight in the USA. Although germ cell tumours have a common cellular origin, they develop at diffuse sites with variation in histology, genetics and biology. 42 If these tumour phenotypes have differential risk relationships with birthweight, then varying proportions within each dataset may explain our apparently contrasting results. For hepatoblastoma, our finding of a non-linear marked association with low birthweight is likely to be driven by the relatively high proportion of babies with birthweights less than 2.0 kg (15.9% and 8.7% for the USA and the UK, respectively, Table 2 ), which would align with previously reported increased risk of hepatobastoma in very low birthweight babies. 43 Strengths and limitations of the study Our study was limited by the lack of information on gestational age, maternal age, plurality, birth order and maternal race/ethnicity for the UK data. As such, we were not able to adjust both datasets for the same covariates. However, comparison of results between datasets demonstrated a striking concordance for the majority of tumours, strongly suggesting that birthweight influences the risk of many childhood cancers independently of these variables. Where we did observe differences in risk between datasets, reanalysis of unadjusted US data had little impact (Table 5 ). These differences may therefore indicate confounding by other factors and/or an impact of tumour heterogeneity or classification differences, as discussed above. It must also be acknowledged that, given the large number of tests performed, some of our findings may be due to chance, and should therefore be interpreted with caution.
Interpretation
We were able to consider gestational age in US, but not UK, data. For the majority of tumours that displayed an increased risk with increasing birthweight in both datasets (Table 3) , ORs were slightly higher for US data. This suggests that although the weight of the baby at birth is important, risk of cancer is principally related to the rate at which the fetus grows. Similar observations have been reported for ALL. 44 In contrast, CNS tumours displayed lower ORs for US data (adjusted) compared with UK data (unadjusted) ( Table 3 ). This is most apparent for the intracranial and intraspinal embryonal tumours, where a strong risk association was only observed for unadjusted US risk estimates. Therefore, for CNS tumours, weight of the newborn may have a greater impact on risk than the rate of fetal growth. This would align with previous reports illustrating that risk of childhood brain tumours increases significantly with increasing head circumference at birth, 45, 46 and suggests that risk may be driven by organ size and pool of susceptible cells at birth. The biological mechanisms linking fetal growth/size and cancer risk are unknown. Since we observe significant risk association with a diversity of otherwise unrelated tumours, there may be a causal relationship with the number, size or proliferative potential of cells in the relevant tissue of the neonate. The number and proliferative potential of muscle stem cells, 47 neuronal progenitor cells 48 and haematopoietic stem cells (HSCs) 49, 50 have all been shown to positively correlate with birthweight. Since these cells are particularly susceptible to oncogenic mutation, a greater proportion of them in a faster-growing or larger fetus may facilitate an increased risk of cancer. This notion is also supported by observations in children with overgrowth disorders such as BeckwithWiedemann syndrome (BWS). These babies, characterized by increased fetal growth rate and/or increased organ size, are prone to a wide range of cancers including Wilms tumour, hepatic tumours, rhabdomyosarcomas, neuroblastoma and leukaemia. 51 BWS is caused by overexpression of the insulin-like growth factor (IGF) 2 gene, and with the established role of IGFs in many adult cancers, it is likely that these high levels contribute to the onset of cancer in these children. Since IGF levels are also increased in heavier babies without these overgrowth syndromes, there may be a more general association between levels of IGF in the neonate and risk of childhood cancer. 5, 6, 19 Further support comes from a recent study describing how babies born with congenital IGF1 deficiency or insensitivity to growth hormones are protected against subsequent risk of developing cancer. 52 The discovery of polymorphic variants of genes in the IGF axis that associate with risk of childhood ALL 53 suggests that there may be a genetic explanation for the increased risk of cancer in children with high birthweights, though it remains to be seen whether this is the case for the diversity of cancers described in the present study. Other postulated mechanisms include exposure of faster-growing/bigger babies to elevated levels of estrogen in utero, as well as other genetic polymorphisms or epigenetic signatures that associate with both fetal growth/ birthweight and cancer risk, discussed in more detail elsewhere. 19 Whether any of these mechanisms would explain the risks observed with low birthweight is unclear. Hepatoblastoma has been associated with very low birthweight in other studies, and the frequent medical interventions often required for these infants and/or maternal smoking may be responsible. 43 However, the graded relationship that we observe with decreasing birthweight perhaps implies the contribution of factors other than medical intervention. Our fractional polynomial analysis suggests that risk relationships for Wilms tumour, intracranial and intraspinal germ cell tumours and AML may also be complex. Each of these relationships may reflect differences in the contribution of specific cell types to tissue growth and development. For example, U-and J-shaped relationships have been reported between birthweight and number of HSCs within umbilical cord blood. 47 If similar relationships exist for other types of stem cells, this may offer a potential explanation of these more complex risk associations.
Here we have presented evidence that risk association between birthweight and some childhood cancers may be influenced by age and sex, as well as population and geographical parameters. We also suggest that risk may be specific to tumour subgroups. Finally, we show that risk of some cancers appears to be independent of birthweight, suggesting that they have distinct aetiologies. These details may be important for future studies aimed at understanding the biological mechanisms underlying the intriguing relationship between growth in utero and cancer in childhood.
Importance and public health impact
Between the 1970 s and the late 1980 s, birthweights gradually increased in several developed countries. 54 Paralleling these trends, the incidence of childhood cancer steadily rose, with average increases of 1% per year (1974 to 1991) in the USA 55 57 Concomitantly, recent figures from the UK suggest that incidence rates of childhood cancer have plateaued since the early 2000 s. 58 In light of the results presented here, one could speculate that these changes in cancer incidence rates may be related to changes in birthweight trends. The proportion of newborns with a high birthweight (!4 kg) in 2012 was approximately 8% in the USA 59 and 11% in England and Wales. 60 Our results would therefore suggest that currently, about one-tenth of newborns have an increased risk of developing cancer in childhood. However, we are now in the midst of a global obesity epidemic, with a recent report that adult obesity has risen so dramatically since 2000 that one in nine people older than 20 years was clinically obese in 2008. 61 This means that the number of women of childbearing age who are obese is on the increase. Since mothers who are overweight/obese are up to twice as likely to give birth to babies weighing !4 kg, 62 birthweights and risks of childhood cancer may once again climb, and with this the necessity to understand the biological mechanisms that drive these risk associations.
